Clinicians' Experiences of Implementing Clinical Frailty Scale Assessments in Lung Oncology Clinics: A Qualitative Interview Study.

Pearce, J.; Hamzeh, H.; Denholm, M.; Greystoke, A.; Gomes, F.; Clegg, A.; Velikova, G.; Richards, SH.; Gilbert, A.

Clinicians' Experiences of Implementing Clinical Frailty Scale Assessments in Lung Oncology Clinics: A Qualitative Interview Study.

All Authors

Pearce, J.

Hamzeh, H.

Denholm, M.

Greystoke, A.

Gomes, F.

Clegg, A.

Velikova, G.

Richards, SH.

Gilbert, A.

LTHT Author

Pearce, Jessica
Velikova, Galina
Gilbert, Alexandra

LTHT Department

Oncology
Leeds Cancer Centre

Publication Date

2026

Item Type

Journal Article

Subject

FRAILTY , GERIATRICS , MEDICAL ONCOLOGY , QUALITATIVE RESEARCH

Abstract

BACKGROUND/OBJECTIVES: Simple frailty assessments, such as the clinical frailty scale (CFS), are prognostic for worse outcomes in older adults with cancer and could support treatment decision-making. This interview study aims to explore clinicians' experiences of using simple frailty assessments in oncology, including the impacts on patient care and barriers and facilitators to successful implementation. METHODS: Semi-structured individual interviews were conducted with clinicians at three UK sites that had implemented CFS screening in lung cancer clinics as part of a national pilot, to explore how frailty assessments are applied and are impacting care. Purposive sampling targeted a range of professionals involved in assessing frailty and making treatment decisions. Recordings were transcribed verbatim and analysed thematically. RESULTS: Ten clinicians participated, and four main themes were identified. 'Assessing fitness and frailty' explores the central role of performance status (PS), as well as its limitations, and what frailty assessments add. 'Scoring and interpreting CFS' describes the ease and relative yield of CFS use, particularly for patients with 'borderline' PS scores (e.g., PS 1-2 or 2-3), and the importance of contextual interpretation. 'Role of frailty and impacts of assessment' highlights how frailty assessments can enhance patient-centered care and support, and clinical and shared decision-making, with potential for streamlined care and system-level benefits. 'Barriers and facilitators to implementation' are described, including time, culture, guidance, and training, with recommendations provided. CONCLUSIONS: Assessing frailty has wide-ranging potential benefits for patients, oncology teams, and the wider system, but barriers must be overcome. Specific recommendations are provided to support the routine implementation of frailty assessments, which is a key step towards the benefits of frailty-informed care being realised at scale.